<table>
<thead>
<tr>
<th>タイトル Title</th>
<th>Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>著者 Author(s)</td>
<td>Yamamoto, Masashi / Kamigaki, Takashi / Yamashita, Kimihiro / Hori, Yuichi / Hasagawa, Hiroshi / Kuroda, Daisuke / Moriyama, Hiroaki / Nagata, Masao / Yonson, Ku / Kuroda, Yoshikazu</td>
</tr>
<tr>
<td>掲載誌・巻号・ページ Citation</td>
<td>Oncology Reports, 22(2): 337-343</td>
</tr>
<tr>
<td>刊行日 Issue date</td>
<td>2009-08</td>
</tr>
<tr>
<td>資源タイプ Resource Type</td>
<td>Journal Article / 学術雑誌論文</td>
</tr>
<tr>
<td>版区分 Resource Version</td>
<td>publisher</td>
</tr>
<tr>
<td>権利 Rights</td>
<td></td>
</tr>
<tr>
<td>DOI</td>
<td>10.3892/or_00000442</td>
</tr>
<tr>
<td>JaLCDOI</td>
<td></td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://www.lib.kobe-u.ac.jp/handle_kernel/90001455">http://www.lib.kobe-u.ac.jp/handle_kernel/90001455</a></td>
</tr>
</tbody>
</table>

PDF issue: 2022-02-01
Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer

MASASHI YAMAMOTO1, TAKASHI KAMIGAKI1, KIMIHIRO YAMASHITA1, YUICHI HORI2, HIROSHI HASEGAWA1, DAISUKE KURODA1, HIROAKI MORIYAMA3, MASAO NAGATA3, YONSON KU2 and YOSHIKAZU KURODA1

Department of Surgery, Divisions of 1Gastro-intestinal Surgery and 2Hepato-Biliary-Pancreatic Surgery, 3Department of Internal Medicine, Division of Internal and Geriatric Medicine, Kobe University Graduate School of Medicine, Kusunoki-cho, Kobe, Hyogo 650-0017, Japan

Received March 5, 2009; Accepted April 30, 2009

DOI: 10.3892/or_00000442

Abstract. Regulatory T cells (Tregs) play an important role in immunological self-tolerance and protect the host from autoimmune disease. However, in cancer immunity, Tregs might block anti-tumor immune responses. Therefore, the depletion of Tregs using a specific agent that suppresses its function or population, such as an anti-CD25 antibody, could promote anti-tumor immune responses. In the present study, a cytotoxicity assay, enzyme-linked immunosorbent spot (ELISPOT) assay and measuring cytokine secretion, were used to study the efficacy of Treg depletion by anti-CD25 antibody added to a dendritic cell/tumor cell (DC/TC) fusion hybrid vaccine in a murine pancreatic cancer model. All the mice treated with the combined therapy of fusion hybrid vaccine and Treg depletion rejected tumor growth in a challenging test, although the rejection rate was 20% both for mice that received the fusion hybrids alone or Treg depletion alone. In addition, combined therapy showed a significantly improved survival in comparison to other treatment or control groups. The NK cell activity for DC/TC fusion + Treg depletion was significantly higher than that for the other treatment groups. Cytotoxic T lymphocyte (CTL) activity for DC/TC could potentially be enhanced by the addition of Treg depletion therapy. The treatments including DC/TC fusion induced IFN-γ secreting effector cells in ELISPOT assays. Furthermore, a cytometric beads array assay used to measure cytokine secretion showed that DC/TC fusion + Treg depletion stimulated the highest levels of IFN-γ Th1/Th2 ratios and Th17. These results demonstrate that Treg depletion combined with DC/TC fusion hybrid vaccine enhanced the efficacy of immunotherapy in pancreatic cancer by activating CTLs and NK cells.

Introduction

Dendritic cells (DCs) are potent antigen-presenting cells (APCs) which are essential to control the defense mechanism of the immune system against tissue-specific antigens, such as viral proteins or auto-antigens. DCs also play an important role in the induction of anti-tumor immune responses by stimulating the generation and proliferation of tumor-specific cytotoxic T lymphocytes (CTLs) and helper T cells (1,2). A large number of immunotherapeutic strategies have used DC vaccines loaded with tumor antigen associated peptides, DNA or RNA. DC vaccines pulsed with tumor lysates or stressed tumor cells have also been shown to elicit an anti-tumor effect in animals and clinical trials (3-5).

The vaccination with DC and tumor cell fusion hybrids (DC/TC hybrids) shows promising efficacy in murine tumor models (6-8). DC/TC hybrids can express multiple tumor antigens in the context of MHC class-I and/or class-II molecules and induce polyclonal immune responses against tumor antigens. Previously, vaccination of DC/TC hybrids was effective for the induction of anti-tumor activity in humans (9-12). However, in cancer immunotherapy, the efficacy of vaccinations is often insufficient to activate the anti-tumor immune response, because of the immune-suppressive effect induced by inhibitory cells, such as regulatory T cells (Treg) in the tumor microenvironment. Treg are defined by their expression of CD4, the interleukin-2 receptor component CD25 and intracellular expression of the transcription factor FoxP3 and play an important role in immunological self-tolerance and in suppressing excessive immune responses (13-16). Tregs suppress the activities or function of CD4(+) and CD8(+) T cells, natural killer (NK) cells, and NKT cells through several pathways, such as the secretion of suppressive cytokines e.g. TGF-β and IL-10, cell-to-cell contacting...
mechanism, and the modulation of APCs function (17-19). In animal models, murine pancreatic adenocarcinoma Pan02 tumors promoted Tregs through TGF-β secretion (20). To overcome the immune suppression of Tregs, the depletion of Tregs could therefore promote anti-tumor immune responses in human (21).

The present study compared the anti-tumor efficacy of the following combination of DC-based vaccine and Treg depletion: Treg depletion with an anti-CD25 antibody, vaccination with DC/TC fusion hybrids and a combination of both in Pan02 tumor models. The relative degree of anti-tumor protection in vivo and the efficacy of anti-tumor effector cells were evaluated by comparing the results of a cytotoxicity assay, while measuring the cytokine secretion from effector cells and enzyme-linked immunosorbent spot assays (ELISPOT).

Materials and methods

Mice. Female C57BL/6 mice aged 6-8 weeks purchased from CLEA Japan Inc (Tokyo, Japan). The mice were housed under pathogen-free conditions at the Animal Maintenance Facility at Kobe University School of Medicine and treated according to the university ethics guidelines for animal use in research.

Pancreatic cancer cell lines. The murine pancreas adenocarcinoma cell line Pan02 was kindly provided by Dr David C. Linehan (Washington University School of Medicine, St. Louis, MO). It was cultured in RPMI-1640 supplemented with 10% fetal bovine serum, 100 μg/ml streptomycin and 100 U/ml penicillin at 37˚C in a humidified atmosphere of 5% CO2.

Dendritic cells. Bone marrow-derived DCs were generated, as previously described (22). Briefly, bone marrow harvested from femurs and tibiae of C57BL/6 mice, was filtered through 100 μm nylon cell strainer (BD Biosciences-Labware, San Jose, CA). The cells were aliquoted to 24-well plates (BD Biosciences-Labware) at 1x10^6 cells/ml RPMI-1640 supplemented with 10% FBS, 100 μg/ml streptomycin and 100 U/ml penicillin at 37˚C in a humidified atmosphere of 5% CO2.

Generation of DCs/tumor cell fusion hybrids. Bone marrow derived DCs were fused to irradiated Pan02 cells (30 Gy) at a ratio of 2:1, respectively, in a solution of polyethylene glycol in DMSO (Sigma-Aldrich), as described previously (23). Briefly, the DC/tumor cell suspension was washed twice with conditioned medium and was then resuspended in 1 ml of 50% polyethylene glycol added over 1 min and stirred gently for 1-2 min. Pre-warmed RPMI-1640 was then slowly added by gently stirring the suspension. After 2 min at 37˚C, the resultant mixture of the cells was grown overnight in a culture medium containing GM-CSF. In the present study, loosely adherent, DC/irradiated tumor cell fusion hybrids were used for vaccination at 24 h after chemical fusion.

Cytotoxicity assay. C57BL/6 mice were divided into the previous four groups and each group contained three mice. Immunizations were done, as described above. At 7 days after tumor challenge, splenocytes were isolated and stimulated with 1.0x10^6 Pan02 cells irradiated with 30 Gy for a day in RPMI-1640 supplemented with 10% FBS, 100 μg/ml streptomycin and 100 U/ml penicillin, 50 μM 2-ME. Splenocytes were collected and tested for their cytotoxic ability. Effector (E) cells were added to target (T) cells (Pan02 cells for CTL assay, YAC-1 for NK cell assay) labeled with 51Cr and cultured for 4 h at various E/T ratios. The percent cytotoxicity was calculated from the release of 51Cr as follows: [(experimental release)-(target spontaneously release)]/[(target maximum release) - (target spontaneously release)] x 100.
Cytokine assay. The mice were divided into four groups as previously described and each group contained three mice. Immunizations and stimulation for a day were done same as described above. The splenocytes were collected and assessed by murine IFN-γ ELISPOT (BD Bioscience). The supernatant was collected and secretion of various cytokines was measured by a cytometric bead array assay (CBA Mouse Inflammation kit, BD Pharmingen) or mouse Interleukin (IL)-17 enzyme-linked immunosorbent assay (ELISA, Bender Med System GmbH, Vienna, Austria). In the CBA assays, 6 cytokines, IFN-γ, IL-6, IL-10, IL-12p70, TNF-α and MCP-1 were measured in the supernatant of the effector cells stimulated with Pan02 cells. In IL-17 ELISA, mouse IL-17 was also measured in the supernatant of splenocyte after 1 or 5 days culture with Pan02 cells.

Statistical analysis. Survival data were described as Kaplan-Meier curves. Statistical significance was determined using Student’s t-test and one-factor ANOVA. P-values <0.05 were considered to be significant.

Results

Treg depletion and fusion vaccination suppressed tumor growth and improved survival. Twenty C57BL/6 mice were divided into four groups and received a combination of Treg depletion and fusion vaccination. All mice were injected with 5x10⁵ Pan02 cells subcutaneously on day 0 and were observed for tumor growth. The tumor size of each mouse was measured until day 60 and the survival was followed up until 120 days after tumor inoculation. All mice immunized both with fusion and anti-CD25Ab rejected tumor growth (5/5). Mice immunized with fusion or anti-CD25Ab demonstrated 20% rejection rate (1/5; Fig. 2). At 56 days after tumor injection, the mean tumor volume for PBS control, anti-CD25Ab, and fusion were 12,050±6,616 mm³, 6,094±2,335 mm³ and 6,813±2,996 mm³, respectively. There are no notable differences in the tumor size between mice given the anti-CD25Ab and fusion hybrid vaccine, however ~50% tumor growth inhibition was observed in mice that received anti-CD25Ab or fusion in comparison to the control. The median survival time was: PBS control, 59 days (range, 56-112); anti-CD25Ab, 71 days (range, 56-112); and fusion, 69 days (range, 56-112); however, for the fusion + anti-CD25Ab group, all mice survived 120 days post-inoculation of tumor cells (Fig. 3). For the control group, all mice died within 10 weeks after inoculation of Pan02 cancer cells. The combination of Treg depletion and fusion vaccination showed a significantly longer survival than Treg depletion only or fusion vaccination only (p<0.03).

CTL and NK cell activity enhanced by combination therapy of Treg depletion and fusion vaccination. The Pan02-specific CTL activity and YAC-1-specific NK cell activity were examined using a 4 h ⁵¹Cr releasing cytotoxity assay. CTL activity for the fusion + anti-CD25Ab group was 10.2, 13.5 and 14.2% at the E/T ratio 12.5:1, 25:1 and 50:1, respectively (Fig. 4). For combined therapy, the CTL activity was significantly higher than that for the control at an E/T ratio of 50:1 (15.8 vs. 9.6%, p<0.05). Although, the CTL activity for fusion + anti-CD25Ab was found to be highest at each E/T ratio, no significant difference was seen between three therapy groups for Pan02-specific CTL activity at the 50:1 E/T ratio. The NK cell activity of fusion + anti-CD25Ab group at the E/T ratio 12.5:1, 25:1 and 50:1 was 22.7, 50.1 and 61.3%, respectively (Fig. 4). The NK cell activity for fusion only or fusion + anti-CD25Ab group was significantly higher than that for PBS control (p<0.005). Fusion + anti-CD25Ab combined therapy showed a significantly higher level of the
Table I. Cytokine production by splenocytes from mice immunized with fusion hybrid vaccine and Treg depletion.

<table>
<thead>
<tr>
<th>Immunization group</th>
<th>IFN-γ (pg/ml)</th>
<th>IL-6 (pg/ml)</th>
<th>IL-10 (pg/ml)</th>
<th>IFN-γ/IL-6</th>
<th>IFN-γ/IL-10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>3.8±0.2</td>
<td>82.4±6.2</td>
<td>N.D</td>
<td>0.046±0.0012</td>
<td>-</td>
</tr>
<tr>
<td>Anti-CD25Ab</td>
<td>17.9±10.2</td>
<td>113.2±29.1</td>
<td>9.8±6.7</td>
<td>0.18±0.13</td>
<td>3.1±1.2</td>
</tr>
<tr>
<td>Fusion</td>
<td>210.9±18.1*</td>
<td>942.6±155.8</td>
<td>115.7±26.2</td>
<td>0.23±0.044</td>
<td>1.9±0.4</td>
</tr>
<tr>
<td>Fusion + anti-CD25Ab</td>
<td>594.9±88.7*</td>
<td>1387.2±174.1</td>
<td>152.2±60.8</td>
<td>0.43±0.018</td>
<td>4.3±1.4*</td>
</tr>
</tbody>
</table>

Splenocytes from mice immunized with PBS, fusion hybrid vaccination, Treg depletion by anti-CD25Ab and fusion hybrid vaccination + Treg depletion by anti-CD25Ab were co-cultured with irradiated Pan02 cells. The supernatant of each culture was collected and examined by CBA assay for assessing production of cytokines. The data are shown as mean ± SD. *Significantly higher than PBS control (p<0.01). **Significantly higher than fusion hybrids (p<0.045).

Figure 4. C57BL/6 female mice were divided into four groups: PBS control, anti-CD25Ab alone, fusion alone and anti-CD25Ab + fusion. Seven days after tumor challenge, splenocytes were isolated and were co-cultured with 1.0x10⁵ irradiated Pan02 cells for one day. Splenocytes were collected and tested for their cytotoxic ability as effector cells. Effector (E) cells were added to target (T) cells (Pan02 or YAC-1) labeled with ⁵¹Cr and co-cultured for 4 h at various E/T ratio. Percent cytotoxicity was calculated from the release of ⁵¹Cr as follows: [(experimental release) - (target spontaneously release)] / [(target maximum release) - (target spontaneously release)] x 100. Cytotoxicity against Pan02 cells showed the CTL activity and that against YAC-1 cells showed NK activity.

Figure 5. ELISPOT assay measured the secretion of IFN-γ from splenocytes. Twelve C57BL/6 mice were divided into four groups: PBS control, anti-CD25Ab, fusion and fusion + anti-CD25Ab. Splenocytes isolated 7 days after tumor challenge subcutaneously were co-cultured with 1.0x Pan02 cells for 24 h. Splenocytes and the culture supernatants were collected and analyzed using ELISPOT and a CBA Mouse Inflammation kit. In ELISPOT assays, each average number of SPC per 1x10⁵ effector cells in the fusion + anti-CD25Ab, fusion, anti-CD25Ab and control was 379±10, 314±86, 197±38 and 54±8, respectively (Fig. 5). The combination of Treg depletion and fusion vaccination showed the highest ability for IFN-γ production of effector cells. The spots for mice that received fusion was slightly lower than that for fusion + anti-CD25Ab, but was significantly higher in comparison to that for anti-CD25Ab (p<0.01). In CBA assays, the mean levels of IFN-γ, IL-6 and IL-10 secretion are shown in Table I. There were no significant differences in other cytokines, such as TNF-α, MCP-1 and IL-12p70. Combined therapy of Treg depletion and fusion vaccination showed the highest levels of IFN-γ, IL-6 and IL-10 secretion of all groups. For mice given anti-CD25Ab monotherapy, secretion of IFN-γ from effector cells was significantly lower than that for mice that received fusion alone or fusion + anti-CD25Ab therapy (17.9 vs. 210.9 or 594.9 pg/ml, respectively; p<0.001). The ratio of IFN-γ/IL-6 or IFN-γ/IL-10 represents the relative ratio of Th1/Th2 cytokine production. The ratio of IFN-γ/IL-6 was significantly higher for the therapy including the fusion hybrids vaccine in comparison to that for the control (p<0.01). Meanwhile, for the anti-CD25Ab treatment regimen, the ratio of IFN-γ/IL-10 was higher than that for fusion monotherapy (p<0.05), because IL-6 could be more dominant for anti-CD25Ab therapy in comparison to IL-10 for Th2 cytokines in the cytokine secretion profiles. In the Th17 assay, for the mice given the combination of fusion and anti-CD25Ab, significantly higher IL-17 secretion was demonstrated in effector cells after stimulation by Pan02 cells for 24 h, in comparison to other.
comparison to the fusion or anti-CD25Ab monotherapy treatment showed significantly improved survival in (26).

depletion of Treg function and population may enhance therapy or cancer vaccines. Several studies have shown that specific anti-tumor immunity induced by adaptive immunotherapy against malignancies. In addition, it may also suppress could suppress the host spontaneous immune response to infectious sites or tumors (24). Tregs maintain migration to infectious sites or tumors (24). Tregs maintain the ability to migrate to sites of inflammation and cancerous tissues (25). In the peripheral blood or tumor microenvironment have been revealed in patients with several kinds of cancer such as pancreatic, and ovarian cancer (25). High levels of Tregs could suppress the host spontaneous immune response against malignancies. In addition, it may also suppress specific anti-tumor immunity induced by adaptive immunotherapy or cancer vaccines. Several studies have shown that the depletion of Treg function and population may enhance the efficacy of immunotherapy in various cancer models (26).

In the present study, fusion + anti-CD25Ab combined treatment showed significantly improved survival in comparison to the fusion or anti-CD25Ab monotherapy groups. The anti-tumor efficacy of fusion hybrids or Treg depletion monotherapy could be essentially equivalent. However, the mechanism of immunotherapeutic efficacy could be different between fusion hybrids and anti-CD25Ab therapy; because different types of effector cell activity and cytokine expression profiles were found in these experiments.

The CTL and NK cell activity for the fusion + anti-CD25Ab group was higher than that for the other treatment groups. These results suggested that Treg depletion and fusion vaccination induced effective anti-tumor immunity by induction of strong effector cells, especially NK cells. However, administration of anti-CD25Ab alone could not elicit NK cell activity in the present study. In assessing the cytokine profiles, both the ELISPOT and CBA assay demonstrated higher IFN-γ levels for the fusion treatment groups, in comparison to anti-CD25Ab monotherapy. Wald et al reported that IFN-γ stimulated the mobilization of NK cells into the circulation, but not their proliferation (27). Furthermore, only DC-activated NK cells are able to produce IFN-γ and mediate anti-tumor protection (28). Therefore, DC-based therapy, such as DC/TIC fusion hybrids are essential for induction of NK cells with anti-tumor potential in Treg depletion therapy.

Fusion hybrid vaccine elicits tumor-specific CTL activity, as well as NK cells in colon adenocarcinoma models (8). However, in the present study, fusion alone failed to induce tumor-specific CTL activity, although significant NK cell activity was found in mice given the fusion vaccine. The therapeutic efficacy for DC/TIC vaccine is insufficient in murine renal cell carcinoma, RenCa, which expresses a high level of TGF-β, although, enhanced therapeutic efficacy was observed when DC/TIC fusion expressing a soluble TGF-β receptor was used (29). Therefore, in Pan02 models which also produce TGF-β, Treg suppressed anti-tumor immunity induced by DC/TIC fusion hybrids through secreted TGF-β. Prasad et al demonstrated that the depletion of Treg did not reveal the activity of CTLs specific for melanocyte differentiation antigens in B16-F10 mouse melanoma models (30). Significant differences in the CTL activity was found only between fusion + anti-CD25Ab combined therapy and control treatments (Fig. 6). However, for the mice given fusion only, IL-17 secretion increased to almost the same level as that for mice received with combined therapy after a 5-day stimulation. These results demonstrate that the combination of Treg depletion and fusion vaccination is the more effective in activation of both Th1 and Th17, in comparison to monotherapy with anti-CD25Ab or fusion hybrids.

Discussion

DC/TC fusion hybrid vaccines demonstrate a more effective anti-tumor immunity than either tumor lysate-pulsed DCs or mixtures of DCs and tumor cells in murine colon cancer models (8). Furthermore, DC/TC fusion hybrids can elicit CTLs specific to various tumor antigens and can be used for promising anti-tumor efficacy in future clinical trials because there is no need to identify tumor-associated antigens.

Tregs which are produced in the thymus are called natural Tregs and those which are altered from the naive T cells in the periphery are called induced Tregs. Natural Tregs are found in the regional lymph nodes where tissue-specific self antigens are presented by dendritic cells and they also migrate to infectious sites or tumors (24). Tregs maintain immune homeostasis by controlling peripheral tolerance against self-antigens. In recent studies, high levels of Tregs in the peripheral blood or tumor microenvironment have been revealed in patients with several kinds of cancer such as pancreatic, and ovarian cancer (25). High levels of Tregs could suppress the host spontaneous immune response against malignancies. In addition, it may also suppress specific anti-tumor immunity induced by adaptive immunotherapy or cancer vaccines. Several studies have shown that the depletion of Treg function and population may enhance the efficacy of immunotherapy in various cancer models (26).

In the present study, fusion + anti-CD25Ab combined treatment showed significantly improved survival in comparison to the fusion or anti-CD25Ab monotherapy.
enhanced more effectively in combined immunotherapy with DC/TC fusion hybrid vaccine.

In the current model, the Treg depletion alone resulted in anti-tumor efficacy *in vivo* similar to fusion monotherapy. However, no NK cell activity was seen and lower levels of Th1 cytokines, such as IFN-γ, was found in mice treated with anti-CD25Ab alone. Foxp3 inhibits the Th17 lineage, but the role of IL-17 in anti-tumor immunity is still unknown (32). A few studies have suggested that Th17 could assume a role in tumor prevention (33). Meanwhile, IL-6 induces the differentiation of Th17 cells (34). The addition of anti-CD25Ab up-regulated IL-6 secretion with a higher Th1/Th2 ratio in comparison to fusion alone. In our study, an early elevation of IL-17 secretion from effector cells was observed for the combination of fusion hybrids and anti-CD25Ab. Therefore, it is theoretically possible that the anti-CD25Ab treatment might enhance the Th17 response and could contribute to improving tumor growth inhibition or survival in combination with DC/TC fusion hybrids. Future studies are therefore needed to examine the effect of fusion + Treg depletion strategies on the Th17 response *in vivo*, because the correlations among Th1, Th2 and Th17 in the anti-tumor immunity of the present combined therapy is still unknown.

In conclusion, the combined immunotherapy of a DC/TC fusion hybrid vaccine and anti-CD25Ab elicited the anti-tumor immune response of NK cells, supported by high levels of IFN-γ, Th1/Th2 ratio and Th17. Furthermore, the combined therapy of Treg depletion and DC/TC fusion vaccine could potentially enhance the CTL activity. In the future, the mechanism of anti-tumor activity by Treg depletion therapy should be investigated by an analysis of various cytokine expression profiles, especially Th17 as well as Th1/Th2.

References


